MA53664A - Composés destinés au traitement de certaines leucémies - Google Patents
Composés destinés au traitement de certaines leucémiesInfo
- Publication number
- MA53664A MA53664A MA053664A MA53664A MA53664A MA 53664 A MA53664 A MA 53664A MA 053664 A MA053664 A MA 053664A MA 53664 A MA53664 A MA 53664A MA 53664 A MA53664 A MA 53664A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- certain leukemia
- leukemia
- certain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733029P | 2018-09-18 | 2018-09-18 | |
| US201962816637P | 2019-03-11 | 2019-03-11 | |
| US201962889929P | 2019-08-21 | 2019-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53664A true MA53664A (fr) | 2022-05-04 |
Family
ID=69774840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053664A MA53664A (fr) | 2018-09-18 | 2019-09-17 | Composés destinés au traitement de certaines leucémies |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10889571B2 (fr) |
| EP (1) | EP3852745A4 (fr) |
| JP (2) | JP7611832B2 (fr) |
| KR (2) | KR20210061377A (fr) |
| CN (3) | CN115215838B (fr) |
| AU (2) | AU2019342102C1 (fr) |
| BR (1) | BR112021004051A2 (fr) |
| CA (1) | CA3110576A1 (fr) |
| CL (1) | CL2021000637A1 (fr) |
| CO (1) | CO2021004704A2 (fr) |
| IL (2) | IL281427B2 (fr) |
| MA (1) | MA53664A (fr) |
| MX (2) | MX2021003093A (fr) |
| NZ (1) | NZ773110A (fr) |
| PE (2) | PE20211644A1 (fr) |
| SG (1) | SG11202102367TA (fr) |
| TW (1) | TWI826525B (fr) |
| WO (1) | WO2020061086A2 (fr) |
| ZA (1) | ZA202101304B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211644A1 (es) | 2018-09-18 | 2021-08-24 | Terns Inc | Compuestos para tratar ciertas leucemias |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020234859B2 (en) | 2019-03-11 | 2025-03-13 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor |
| WO2021018194A1 (fr) * | 2019-07-29 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Composés hétérocycliques utilisés en tant qu'inhibiteurs de bcr-abl |
| EP4017875A4 (fr) | 2019-08-23 | 2023-05-03 | Terns Pharmaceuticals, Inc. | Composés agonistes du récepteur bêta de l'hormone thyroïdienne |
| AU2020346057A1 (en) | 2019-09-12 | 2022-04-21 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| US20240059682A1 (en) * | 2021-03-03 | 2024-02-22 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN116375650B (zh) * | 2022-12-30 | 2025-08-05 | 浙江美诺华药物化学有限公司 | 一种替戈拉生中间体的制备方法 |
| WO2024211898A1 (fr) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Association comprenant un agoniste thrbeta anda glp-1r destiné à être utilisé dans le traitement d'un trouble du foie ou d'une maladie cardiométabolique |
| TW202525293A (zh) * | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
| WO2025226724A1 (fr) * | 2024-04-23 | 2025-10-30 | Terns Pharmaceuticals, Inc. | Inhibiteurs de bcr-abl1 destinés à être utilisés dans le traitement du cancer |
| CN120842151A (zh) * | 2024-04-26 | 2025-10-28 | 北京英飞智药科技有限公司 | 一种2-芳基苯并咪唑类化合物及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516276A (ja) * | 1998-05-22 | 2002-06-04 | アバニール・ファーマシューティカルズ | ＩｇＥのモジュレータとしてのベンゾイミダゾール誘導体 |
| SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| PE20061378A1 (es) * | 2005-04-20 | 2006-12-03 | Smithkline Beecham Corp | INHIBIDORES DE LA ACTIVIDAD DE Akt |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| CN101553468A (zh) * | 2006-10-18 | 2009-10-07 | 诺瓦提斯公司 | 有机化合物 |
| GB0800035D0 (en) | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
| WO2013033093A1 (fr) | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Composés hétérocycliques utilisables en tant qu'inhibiteurs des janus kinases |
| CN104334529B (zh) | 2012-05-15 | 2017-03-15 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 |
| US9340537B2 (en) | 2012-05-15 | 2016-05-17 | Novatis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| JP6078639B2 (ja) | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| JP2019515932A (ja) | 2016-04-29 | 2019-06-13 | アスター バイオテック リミテッド ライアビリティ カンパニー | チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物 |
| WO2018133827A1 (fr) | 2017-01-20 | 2018-07-26 | 深圳市塔吉瑞生物医药有限公司 | Composé (hétéro)arylamide pour inhiber l'activité de la protéine kinase |
| US10875853B2 (en) | 2017-01-20 | 2020-12-29 | Shenzhen Targetrx, Inc. | (Hetero)arylamide compound for inhibiting protein kinase activity |
| WO2018191146A1 (fr) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Inhibiteurs de rheb à base d'hétéroaryle et leurs utilisations |
| WO2019173761A1 (fr) | 2018-03-09 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composé inhibiteur de tyrosine kinase c-abl, modes de réalisation, procédés de fabrication et d'utilisation associés |
| PE20211644A1 (es) | 2018-09-18 | 2021-08-24 | Terns Inc | Compuestos para tratar ciertas leucemias |
| EP4329749A4 (fr) | 2021-04-27 | 2025-03-19 | Merck Sharp & Dohme LLC | Inhibiteurs à petites molécules de mutant de kras g12c |
| IL311791A (en) | 2021-09-30 | 2024-05-01 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | A compressed four-membered cyclic compound and a method of its preparation and use |
| CN120981465A (zh) | 2023-03-30 | 2025-11-18 | 江苏豪森药业集团有限公司 | 四元稠环类化合物盐晶型及其制备方法和应用 |
| TW202525293A (zh) | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
-
2019
- 2019-09-17 PE PE2021000343A patent/PE20211644A1/es unknown
- 2019-09-17 NZ NZ773110A patent/NZ773110A/en unknown
- 2019-09-17 CN CN202210968772.9A patent/CN115215838B/zh active Active
- 2019-09-17 JP JP2021539486A patent/JP7611832B2/ja active Active
- 2019-09-17 CA CA3110576A patent/CA3110576A1/fr active Pending
- 2019-09-17 PE PE2025001942A patent/PE20252740A1/es unknown
- 2019-09-17 BR BR112021004051-0A patent/BR112021004051A2/pt unknown
- 2019-09-17 CN CN201980060896.3A patent/CN112770745B/zh active Active
- 2019-09-17 CN CN202210969394.6A patent/CN115448908B/zh active Active
- 2019-09-17 SG SG11202102367TA patent/SG11202102367TA/en unknown
- 2019-09-17 KR KR1020217011001A patent/KR20210061377A/ko active Pending
- 2019-09-17 TW TW108133432A patent/TWI826525B/zh active
- 2019-09-17 IL IL281427A patent/IL281427B2/en unknown
- 2019-09-17 AU AU2019342102A patent/AU2019342102C1/en active Active
- 2019-09-17 MX MX2021003093A patent/MX2021003093A/es unknown
- 2019-09-17 IL IL322515A patent/IL322515A/en unknown
- 2019-09-17 WO PCT/US2019/051567 patent/WO2020061086A2/fr not_active Ceased
- 2019-09-17 EP EP19862388.6A patent/EP3852745A4/fr active Pending
- 2019-09-17 MA MA053664A patent/MA53664A/fr unknown
- 2019-09-17 US US16/573,860 patent/US10889571B2/en active Active
- 2019-09-17 KR KR1020267002852A patent/KR20260019669A/ko active Pending
-
2021
- 2021-02-25 ZA ZA2021/01304A patent/ZA202101304B/en unknown
- 2021-03-16 MX MX2023007714A patent/MX2023007714A/es unknown
- 2021-03-16 CL CL2021000637A patent/CL2021000637A1/es unknown
- 2021-04-15 CO CONC2021/0004704A patent/CO2021004704A2/es unknown
-
2023
- 2023-06-22 US US18/339,516 patent/US12240835B2/en active Active
-
2024
- 2024-12-20 AU AU2024287115A patent/AU2024287115A1/en active Pending
- 2024-12-24 JP JP2024227127A patent/JP2025066704A/ja active Pending
-
2025
- 2025-01-30 US US19/041,557 patent/US20250276961A1/en active Pending
- 2025-03-06 US US19/072,824 patent/US12454524B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3852745A4 (fr) | Composés destinés au traitement de certaines leucémies | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| EP3956033A4 (fr) | Composés bicycliques | |
| EP3802467A4 (fr) | Composés spirocycliques | |
| MA52948A (fr) | Composés | |
| EP3781156A4 (fr) | Composés spirocycliques | |
| MA51669A (fr) | Composés | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA53003A (fr) | Composés | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| EP3340971A4 (fr) | Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine | |
| EP3853210A4 (fr) | Composés antibactériens | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3897626C0 (fr) | Tinostamustine pour le traitement du myélome multiple | |
| IL282311A (en) | Use of reboxetine to treat narcolepsy | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3349793A4 (fr) | Anti-s100a8 pour le traitement de la leucémie | |
| EP4077318A4 (fr) | Composés | |
| MA52946A (fr) | Composés | |
| EP3416645A4 (fr) | Composés pour le traitement du paludisme | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| EP3852816A4 (fr) | Méthodes de traitement de cancer | |
| IL282700A (en) | Heterocyclic compounds for the treatment of epilepsy | |
| MA45552A (fr) | Compositions destinées au traitement de l'amylose |